{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:21:31Z","timestamp":1792794091383,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2110,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"UCL Clinical Trials Unit"},{"name":"Cancer Research UK with gemcitabine provided by Lilly Oncology","id":[{"id":"https:\/\/ror.org\/054225q67","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Health"},{"name":"Labour and Welfare, Health Labour Sciences Research Grant"},{"DOI":"10.13039\/501100012317","name":"UCLH\/UCL Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/annonc\/mdt540","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T00:40:50Z","timestamp":1387413650000},"page":"391-398","source":"Crossref","is-referenced-by-count":338,"title":["Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials"],"prefix":"10.1016","volume":"25","author":[{"given":"J.W.","family":"Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jitlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Beare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt540_bb0010","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2005.03.040","article-title":"Cholangiocarcinoma","volume":"128","author":"Lazaridis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdt540_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdn533","article-title":"Epidemiology of biliary tract cancers: an update","volume":"20","author":"Randi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt540_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jjco\/hyl158","article-title":"International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII","volume":"37","author":"Matsuda","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdt540_bb0025","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968\u20131998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdt540_bb0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdt540_bb0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","article-title":"Changing international trends in mortality rates for liver, biliary and pancreatic tumours","volume":"37","author":"Khan","year":"2002","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt540_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","article-title":"Diagnosis and treatment of cholangiocarcinoma","volume":"9","author":"Anderson","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt540_bb0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdt540_bb0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt540_bb0055","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt540_bb0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt540_bb0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study\u2014the UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt540_bb0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt540_bb0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt540_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2010.10.009","article-title":"Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer","volume":"80","author":"Furuse","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt540_bb0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","article-title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study","volume":"49","author":"Walter","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt540_bb0090","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","article-title":"Outcome of second-line chemotherapy for biliary tract cancer","volume":"49","author":"Bridgewater","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt540_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12029-010-9242-0","article-title":"Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer","volume":"43","author":"Roth","year":"2012","journal-title":"J Gastrointest Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/2\/391\/475647\/mdt540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:35:58Z","timestamp":1624505758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419364580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0923753419364580"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt540","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}